Simeon George, CEO of life sciences investor SR One, speaks to Unquote about raising its first-time fund, the ongoing importance of its relationship with GSK following its spin-out from the company, and the firm’s deal pipeline.
SR One set to deploy $500m fund following GSK spin-out
Most Popular
